1. Hydroxytyrosol supplementation increases vitamin C levels in vivo. A human volunteer trial
- Author
-
Eduardo López-Huertas, Juristo Fonollá, and Ministerio de Economía y Competitividad (España)
- Subjects
Male ,0301 basic medicine ,Antioxidant ,medicine.medical_treatment ,Clinical Biochemistry ,Blood lipids ,Blood Pressure ,MCHC, mean corpuscular hemoglobin concentration ,Ascorbic Acid ,AST, aspartate aminotransferase ,030204 cardiovascular system & hematology ,Kidney Function Tests ,MCV, mean corpuscular volume ,Biochemistry ,CPK, creatine phosphokinase ,Body Mass Index ,HDL-C, high-density lipoprotein cholesterol ,chemistry.chemical_compound ,0302 clinical medicine ,Liver Function Tests ,TAC, total antioxidant capacity ,ICAM, intercellular cell adhesion molecule 1 ,Hyperlipidemia ,Hydroxytyrosol ,lcsh:QH301-705.5 ,Volunteer ,lcsh:R5-920 ,biology ,medicine.diagnostic_test ,Chemistry ,Phenylethyl Alcohol ,Polyphenolics ,TG, triacylglycerols ,Lipids ,Healthy Volunteers ,Human study ,CRP, ultrasensitive C-reactive protein ,Serum iron ,Female ,GGT, Gamma glutamyl transferase ,lcsh:Medicine (General) ,Research Paper ,Adult ,medicine.medical_specialty ,Iron ,MCH, mean corpuscular hemoglobin ,VCAM, vascular cell adhesion molecule 1 ,03 medical and health sciences ,Folic Acid ,HCT, hematocrit ,ALT, alanine aminotransferase ,Internal medicine ,Lpa, lipoprotein a ,medicine ,Humans ,ox-LDL, oxidized LDL ,MDA, malondialdehyde ,030109 nutrition & dietetics ,ALP, alkaline phosphatase ,Vitamin C ,Organic Chemistry ,Hcy, homocysteine ,Lipid Metabolism ,medicine.disease ,TC, total cholesterol ,Ferritin ,Endocrinology ,lcsh:Biology (General) ,Dietary Supplements ,Immunology ,biology.protein ,LDL-C, low-density lipoprotein cholesterol ,Vitamin c ,LD, lactate dehydrogenase ,Olive oil - Abstract
Hydroxytyrosol (HT) is a main phenolic component of olive oil. In this study, we investigated the safety and effects produced by HT purified (99.5%) from olive mill waste. HT was administered at a daily dosage of 45 mg for 8 weeks to volunteers with mild hyperlipidemia (n=14). We measured markers of cardiovascular disease risk, enzyme markers of several clinical conditions, hematology, antioxidant parameters, vitamins and minerals at baseline (T0), 4 weeks (T4) and 8 weeks (T8). The values obtained at T4 and T8 were compared with baseline. We found that the HT dose administered was safe and mostly did not influence markers of cardiovascular disease, blood lipids, inflammatory markers, liver or kidney functions and the electrolyte balance. Serum iron levels remained constant but a significant (P, The authors wish to thank Puleva Biotech SA and the Spanish Ministry of Economy and Competitiveness (formerly Ministry of Science and Innovation) [the ERDF-cofinanced grant AGL2011-24428], for funding. The authors wish to thank Maria González-Santiago, Carlos Rodríguez and Antonio D. Valero for their valuable technical assistance, Dr Luis Perez for the purification of the HT used in the study, Alberto Zafra for his help with the HPLC and GC-MS analytical procedures, Dr Arjan Geerlings for fruitful discussions and Ruth Wilson for revising the manuscript.
- Published
- 2017